15. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-2284 Background: The prognostic value of the NIH consensus criteria for graft-versus-host disease (GVHD) is not well defined yet.
introduction
In 2005, an NIH consensus conference introduced standardized criteria for the diagnosis of chronic graft-versushost disease (GVHD) as well as a new organ-specific and global severity score [1] . In addition, four new GVHD subcategories were defined [classic acute GVHD (aGVHD), late aGVHD, classic chronic GVHD (cGVHD), overlap syndrome], which allowed distinction of aGVHD and cGVHD based on clinical criteria rather than referring to a cut-off day 100, as done previously [2] . Although the NIH criteria were well accepted by the clinical community [3] , and various studies assessed their prognostic value in mixed populations [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , data regarding their prognostic value in single indications are still very limited [16] . Nonetheless, an indication-specific assessment is warranted, as the detrimental effects of GVHD may be counteracted by a beneficial graft-versus-leukemia (GVL) effect, the strength of which depends upon the underlying condition [17, 18] . In that respect, the GVL effect is strongly established in chronic myeloid leukemia, where cessation of immunosuppression or administration of donor lymphocyte infusions (DLI) is often effective in treating relapse [19] ; however, in more rapidly proliferating diseases, particularly in acute lymphoblastic leukemia (ALL), the GVL effect is considered to be less robust [19] [20] [21] . It has been speculated that ALL cells can escape the immunologic attack of the allogeneic cells due to the induction of T-cell anergy [22] , inadequate co-stimulation [23] and insensitivity to NK cells [24] , and an intrinsic resistance to GVL effects was postulated by some authors [21] . Accordingly, only some [25, 26] but not all studies [27] , which used the historic classification for GVHD, were able to identify a clear association of cGVHD and relapse risk in ALL patients. In the present study, using the new, more biology-based, NIH classification of GVHD, we aimed to re-investigate the susceptibility of ALL to GVL effects. Our report includes data on 147 consecutive ALL patients who received a myeloablative allogeneic hematopoietic cell transplantation (HCT) at our center between 1995 and 2009. We present (i) the first assessment of the natural history of NIH-defined GVHD in ALL patients; (ii) a detailed analysis of the prognostic value of NIH-defined GVHD according to subcategory and severity and (iii) a subgroup analysis of GVL effects in 44 patients who received pre-emptive, prophylactic or therapeutic DLI.
design and methods patients
The present analysis includes 147 consecutive patients with ALL who received a first myeloablative HCT at our center between May 1995 and October 2009 (Table 1 ). All patients had been initially treated according to German Multicenter Study Group for Adult ALL (GMALL) protocols [28] . All patient-, disease-and transplant-related characteristics and follow-up information including occurrence of aGVHD and cGVHD according to Glucksberg and Shulman criteria [29, 30] were prospectively recorded in an electronic database. Data for reclassification of GVHD according to the NIH consensus criteria [1] were gathered by standardized abstraction of patient files. The study was approved by the local ethics committee and all patients gave informed consent for the analysis of their data, in accordance with the Declaration of Helsinki.
conditioning regimen and transplantation procedure
The conditioning was myeloablative based on 12 Gy total body irradiation ± etoposide ± cyclophosphamide (n = 143), busulfan + cyclophosphamide (n = 2) or treosulfan + etoposide + 
GVHD prophylaxis
GVHD prophylaxis was based on cyclosporine A (CSA) in all cases, which, depending on treatment period, donor type, prior complications or contraindications, was given alone (n = 4; 3%) or in combination with short-course methotrexate (n = 106; 72%), mycophenolate mofetil (MMF) (n = 9; 6%) or prednisolone (n = 28; 19%). Anti-T-cell globulin (ATG) Fresenius (10 or 20 mg/kg/day × 3 days) was given in patients with a mismatched donor and, according to GMALL protocols, from 2004 also in patients with matched unrelated donors (n = 35; 24%). Tapering of CSA was generally not begun earlier than day +90 in patients transplanted from a matched donor and not earlier than day +120 in patients transplanted from a mismatched donor.
donor lymphocyte infusions DLI were given to 44 patients (30%) in a pre-emptive [ persistence or recurrence of mixed chimerism (n = 16) or molecular markers (n = 3)] or prophylactic setting [ planned DLI for patients with active disease at transplantation (n = 15)] or for morphological relapse after being treated with reinduction chemotherapy (n = 10). DLI were given in 4-week intervals in escalating doses. After HCT from a related donor, patients received 1 × 10 7 , 5 × 10 7 and 1 × 10 8 CD3+ cells/kg; after unrelated HCT, an additional first 5 × 10 6 CD3+ cells/kg dose was given [31, 32] .
diagnosis, classification and treatment of GVHD aGVHD, late aGVHD, classic cGVHD and overlap syndrome were classified according to the NIH consensus criteria [1] (Supplementary Methods, available at Annals of Oncology online). Classic and late aGVHD severity grades were assigned according to the Glucksberg criteria [29] . In aGVHD, corticosteroids plus continuation of CSA were the standard treatment. Patients with cGVHD requiring systemic treatment also received corticosteroids with or without CSA. For steroid resistant cases, a variety of treatments were used, including MMF, PUVA, sirolimus, azathioprin, cyclophosphamide, rituximab and extracorporeal photopheresis. (two-sided) for all tests. Overall survival (OS) and leukemia-free survival (LFS) were determined with Kaplan-Meier curves and tested univariately using the log-rank test. Relapse, NRM, engraftment and aGVHD and cGVHD were estimated as cumulative incidence, taking into account competing risks: (i) death without relapse in the case of relapse; (ii) relapse in the case of NRM; (iii) death before day 28 without engraftment in the case of engraftment and (iv) death, relapse and DLI in the case of aGVHD and cGVHD. Univariate and multivariate analyses of the association of various risk factors with time-to-event variables were done using the Cox proportional hazard regression analysis, and results are reported as hazard ratios (HR) with 95% confidence intervals (95% CI). Prognostic variables examined were gender, age, Karnofsky performance status (KPS), HCTspecific comorbidity index (HCT-CI), disease status, lineage, donor type, donor age, stem cell source, application of ATG, recipient/donor ABO compatibility, recipient/donor cytomegalovirus status and recipient/donor gender match. GVHD was introduced into the model as a time-dependent covariate at the last step [33] . results engraftment, survival, relapse, non-relapse mortality
Leukocyte engraftment was observed after a median of 17 days (8-37), and platelet engraftment was observed after a median of 20 days (3-121). Five-year OS for the whole cohort was 43% (95% CI: 35%-51%) and 5-year LFS was 41% (95% CI: 33%-50%) ( Figure 1A ). The 5-year cumulative incidence of relapse was 33% (95% CI: 26%-41%) and of NRM, 26% (95% CI: 20%-34%) ( Figure 1B ). The cause of death was relapse in 47 patients (32%), aGVHD in 14 patients (10%), cGVHD in 10 patients (7%), infections in 12 patients (8%) and other causes in 4 patients (3%).
classic aGVHD
The cumulative incidence of classic aGVHD grades I-IV after transplant was 63% (95% CI: 56%-72%), with cumulative incidences of grade I/II of 39% (95% CI: 32%-48%) and of grade III/IV of 24% (95% CI: 18%-33%). The cumulative incidence of classic aGVHD was significantly lower in patients conditioned with ATG [49% (95% CI: 39%-63%)] compared with without ATG [75% (95% CI: 67%-83%)] (P = 0.0085), without being counteracted by a shift toward late aGVHD, overlap syndrome or classic cGVHD (data not shown). Median (Figure 2A ), which was not significantly different for patients with or without ATG application (data not shown). Skin, liver and gut were involved in 88%, 31% and 31% of cases. In multivariate Cox regression analysis, significant risk factors for the development of classic aGVHD were age >50 years [HR 2.049 (95% CI: 1.17-3.57), P = 0.011)], PBSC as stem cell source [HR 1.61 (95% CI: 1.00-2.58), P = 0.05)] and conditioning without ATG [2.079 (95% CI: 1.23-2.51), P = 0.006], whereas gender, KPS, HCT-CI, disease status, lineage, donor type, donor age, recipient/donor ABO compatibility, recipient/donor cytomegalovirus status and recipient/donor gender match had no significant impact.
To determine the prognostic impact of classic aGVHD, we carried out multivariate Cox regression analysis, including GVHD as a time-dependent covariate ( Table 2) . We found that classic aGVHD grade III/IV was associated with inferior OS [HR 2.42 (95% CI: 1.43-4.09), P = 0.001], which was due to higher NRM [HR 4.38 (95% CI: 1.98-9.67), P < 0.001], whereas classic aGVHD grade I/II had no impact on OS but led to reduced relapse incidence [HR 0.44 (95% CI: 0.21-0.89), P = 0.024], which was independent of subsequent development of cGVHD in multivariate analysis.
late aGVHD
Late aGHVD was a rare event with a cumulative incidence of 12% (95% CI: 7%-18%) [grade I/II: 5% (95% CI: 3%-8%), grade III/IV: 6% (95% CI: 3%-12%)] ( Figure 2B ). Fifty-three percent of late aGVHD cases were subclassified as persistent and 40% as recurrent classic aGVHD, whereas only 7% of patients were subclassified as de novo late onset aGVHD. Skin, liver and gut were affected in 60%, 60% and 40% of late aGVHD cases.
No significant impact of late aGVHD on OS could be identified, but severe late aGVHD grade III/IV was associated with higher NRM [HR 3.32 (95% CI: 1.12-9.88), P = 0.031] ( Table 2) .
cGVHD cGVHD occurred at a median of 115 days after transplant (range: 24-464 days). The 3-year cumulative incidence of cGHVD of any grade was 41% (95% CI: 34%-50%), with cumulative incidences of mild, moderate or severe cGVHD of 11% (95% CI: 7%-17%), 12% (95% CI: 7%-18%) and 19% (95% CI: 13%-26%), respectively ( Figure 2C) . Skin, mouth, eyes, gut, liver, lung, joints and facia, genital tract or other organs were involved in 67%, 88%, 65%, 17%, 50%, 15%, 27%, 2% and 6% of cases. cGVHD was subclassified as persistent, quiescent or de novo in 27%, 38% and 35% of cases. Among patients with cGVHD, 38% had classic cGVHD, whereas 62% had an overlap syndrome where signs of aGVHD and cGVHD were seen concomitantly ( Figure 2D ). Significant risk factors for the development of cGVHD in multivariate analysis were age >50 years [HR 1.80 (95% CI: 1.016-3.19), P = 0.044)] and PBSC as stem cell source [HR 2.65 (1.42-4.95), P = 0.002)]. Table 2) . Improved OS was due to a reduced relapse rate [mild cGVHD: HR 0.26 (95% CI: 0.07-0.93), P = 0.038; moderate cGVHD: HR 0.23 (95% CI: 0.071-0.75), P = 0.015; severe cGVHD: HR 0.12 (95% CI: 0.042-0.36); P < 0.001], whereas no significant impact of cGVHD on NRM was seen. Importantly, positive effects of cGVHD on OS and relapse rate were seen in all disease stages, i.e. CR1, CR>1 or no CR (CR, complete remission) (data not shown). Owing to limited sample size, we were not able to evaluate the different severity grades of classic and overlap cGVHD; however, across all severity grades, we found no differential prognostic impact of these two subcategories. Also, no significant difference was seen for persistent, quiescent or de novo type of onset (data not shown).
effect of DLI
Overall, 44 patients received DLI in a pre-emptive or prophylactic setting or after being treated with reinduction chemotherapy for morphological relapse. DLI were given only after the cessation of immunosuppression and only in patients without GVHD. Median time to first DLI was 144.5 days (29-644), median number was 2 (1-4) and median cumulative cell dose was 1.5 × 10 7 CD3+ cells/kg (5 × 10 6 -1.65 × 10 8
). The cumulative incidence of classic aGVHD and late aGVHD after DLI was 60% (95% CI: 46%-76%) [grade I/II: 32% (95% CI: 21%-49%); grade III/IV: 27% (95% CI: 17%-44%) and 5% (95% CI: 1%-18%)], which was comparable with incidence rates after transplant. The cumulative incidence of cGVHD after DLI was 57% (95% CI: 44%-76%) (mild: 21% (95% CI: 11%-36%), moderate 14% (95% CI: 7%-29%), severe 23% (95% CI: 13%-39%)], which appeared to occur more frequently than after transplant. Median time of onset of classic aGVHD after DLI was 20 days (3-76), which was comparable with aGVHD after transplant, and for cGVHD, it was 86 days (14-294), which was somewhat earlier than cGVHD after transplant. Organ involvement in aGVHD and cGVHD was comparable for DLI-or non-DLIassociated GVHD, with the exception of cGVHD of the lung, which occurred in 15% of non-DLI cases, but was not seen after DLI (P = 0.048) (Supplementary Table S1 , available at Annals of Oncology online).
In the pre-emptive setting, 12 of 16 patients with mixed chimerism could be converted to complete donor chimerism and 10 of 16 remained alive in CR. Three patients who Prognostic variables examined were gender, age, Karnofsky performance status, HCT-CI, disease status, lineage, donor type, donor age, stem cell source, application of ATG, recipient/donor ABO compatibility, recipient/donor cytomegalovirus status and recipient/donor gender match. The occurrence of aGVHD, late aGVHD and cGVHD was forced into the multivariate Cox model as a time-dependent covariate at the last step. Patients without leukocyte engraftment were excluded from the analysis and patients who received a second transplant were censored at the time of second transplant. HR and P-values refer to the comparison of the respective category with the first one. HR, hazard ratio; CI, confidence interval; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; DLI, donor lymphocyte infusions; OS, overall survival; NRM, non-relapse mortality. To further elucidate the role of GVL effects in ALL, we analyzed the impact of cGVHD developing after DLI in a timedependent multivariate Cox regression analysis. Comparable with the situation after transplant, we found that patients who developed NIH-defined cGVHD after DLI had improved OS (HR 0.21, 95% CI: 0.054-0.81, P = 0.023) and a lower relapse incidence (HR 0.26, 95% CI: 0.043-0.91, P = 0.048), but no increased NRM. Five-year OS in the pre-emptive and prophylactic setting was 57% (95% CI: 39%-74%), whereas 5-year OS in the relapse setting after chemotherapy was only 10% (95% CI: 2%-29%). Cause of death after DLI was relapse in 16 patients (36%), aGVHD in 3 patients (7%), cGVHD in 2 patients (5%), infections in 1 patients (2%) and other causes in 4 patients (9%). discussion aGVHD and cGVHD are the most relevant complications of allogeneic HCT. Nevertheless, accompanying GVL reactions can counterbalance their detrimental effects and may result in an overall positive impact of the alloreaction [17, 18] . The 2005 NIH consensus classification now allows a more biology-based stratification of GVHD with improved organ-specific and global severity scoring, potentially supporting a more accurate assessment of the differential impact of GVHD and GVL. To date, the vast majority of studies on NIH-defined GVHD have presented data on mixed populations [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] ; however, owing to the heterogeneous response to GVL effects [17, 18] , the true prognostic impact of the new classification should be preferentially studied in single-disease entities [16] .
We here present the first report on the use of the NIH consensus classification for diagnosing and staging GVHD in a cohort of ALL patients. We chose to target ALL because of the limited response to DLI [19] [20] [21] , which has led to questions about the relevance of GVL effects as such in this disease [21] . Prior reports in ALL patients which had used the conventional classification of GVHD were often limited by small patient numbers or inadequate statistics not accounting for timedependent effects [34] [35] [36] .
In our study, now using multivariate Cox regression models with time-dependent covariates, which is regarded as the appropriate method for the analysis of GVHD [33] , we found that NIH-defined cGVHD of any grade was associated with superior OS due to lower relapse incidence. Importantly, this effect was evident for all disease stages. Furthermore, we found that induction of cGVHD by DLI led to improved OS and to a reduction in relapse rate. In addition, we found that DLI were able to convert mixed to complete donor chimerism and to treat the reoccurrence or persistence of molecular markers. These findings provide strong evidence for the relevance of GVL reactions in ALL patients and resolve the disagreement of earlier studies which had used the historic classification for GVHD and which may have been impacted by inappropriate classification of GVHD [25, 26, [34] [35] [36] . With respect to the new subcategories classic and overlap cGVHD, no differential prognostic impact was seen, confirming results from some [7, [10] [11] [12] but not all prior studies, which had been done in mixed populations [9] .
Classic aGVHD grade III/IV was associated with inferior OS due to higher NRM, confirming findings for the conventional GVHD definition [34, 35] . Interestingly, classic aGVHD grade I/II was associated with reduced relapse incidence independent of later development of cGVHD, which suggests that GVL effects may already be relevant at early time points. True lateonset aGVHD was a rare event in our study, which is in line with prior studies in other disease entities [15, 16] . The clinical similarities of classic aGVHD and late aGVHD and the comparable prognostic impact establish the new entity late aGVHD as an important distinction from cGVHD [7, 11, [14] [15] [16] .
Our findings on incidence rates, time-until-onset, organ involvement and severity grades provide first insight into the natural history of NIH-defined GVHD in ALL after myeloablative conditioning and can assist in patient counseling. In broad terms, our findings recapitulate clinical characteristics described in studies which had used the old classification [34, 35, 37, 38] . Regarding risk factors for the development of GVHD, we confirm that older patient age and administration of growth factor-mobilized peripheral blood leukocytes are associated with higher rates of aGVHD and cGVHD, whereas the application of ATG is protective against aGVHD but less against cGVHD [39] [40] [41] [42] [43] . Importantly, donor type had no significant impact on GVHD incidence [44] .
With regard to the overall benefit of DLI, we found that the application of DLI was generally well tolerated without significant acute side-effects on the day of administration. The cumulative incidence of aGVHD and cGVHD after DLI was 60% and 57%, respectively, but this did not lead to excess death rates due to GVHD (12%) or infections (2%). Moreover, the 5-year OS rate of 57% in patients who received DLI in a pre-emptive or prophylactic setting appears promising. However, the 5-year OS rate of 10% in the therapeutic setting shows that DLI have limited activity in ALL once hematologic relapse has occurred. This underlines the notion that effective immunotherapeutic strategies in acute leukemia need to be primarily directed to prevent rather than treat relapse [31, [45] [46] [47] .
In summary, our study demonstrates for the first time that the new NIH criteria for the classification of GVHD can define distinctive prognostic subgroups in patients transplanted for ALL. Importantly, using these new criteria and a statistical approach which avoids selection and lead time bias by evaluating DLI-induced GVHD, we now give convincing evidence for a potent GVL effect in ALL patients. Overall, our findings support the search for immune-mediated relapse prophylaxis or therapy after allogeneic HCT for ALL, with the ultimate goal being to achieve a GVL effect independent of GVHD.
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